Browse Biomarkers Based on Biomarker Basis

This page shows data for Mutation Based biomarker basis.
Total Entries Retrieved: 157
IDBiomarkerBiomoleculeSubjectsRegulationTypeExperimentLevel of SignificanceSourcePMID
277 Mutation of PTEN mRNA Humans Deletion found in patients with Biochemical Recurrence Prognostic Biochemical Recurrence Vs no Recurrence p=0.0009 Tissue 18500259
468 DNA Ploidy - Diploid Mutation Humans DIPLOID: 5 year disease free survival - (80.5% ); 10 year disease free survival - (72.9%) Prognostic 5 and 10 years disease free survival Vs no survival p<0.001 Tissue 19633362
469 DNA Ploidy - Tetraploid Mutation Humans TETRAPLOID: 5 year disease free survival - (67.8% ); 10 year disease free survival - (61.6%) Prognostic 5 and 10 years disease free survival Vs no survival p<0.001 Tissue 19633362
470 DNA Ploidy - Aneploid Mutation Humans ANUEPLOID: 5 year disease free survival - (49.5% ); 10 year disease free survival - (31.8%) Prognostic 5 and 10 years disease free survival Vs no survival p<0.001 Tissue 19633362
471 DNA Ploidy - Diploid Mutation Humans DIPLOID: 5 year disease free survival - (88.7% ); 10 year disease free survival - (84.8%) Prognostic 5 and 10 years disease free survival Vs no survival for Gleason Score=7 p<0.001 Tissue 19633362
472 DNA Ploidy - Tetraploid Mutation Humans TETRAPLOID: 5 year disease free survival - (74.3% ); 10 year disease free survival - (64.7%) Prognostic 5 and 10 years disease free survival Vs no survival for Gleason Score=7 p<0.001 Tissue 19633362
473 DNA Ploidy - Anueploid Mutation Humans ANUEPLOID: 5 year disease free survival - (25.0% ); 10 year disease free survival - (0%) Prognostic 5 and 10 years disease free survival Vs no survival for Gleason Score=7 p<0.001 Tissue 19633362
519 EGFR [SNP rs884419] Mutation Humans AG And GG Phenotypes associated with decreased risk of recurrence Prognostic Biochemical recurrence Vs No recurrence A/G Phenotype: p= 0.0018; G/G Phenotype: p = 0.0016 Tissue 20303520
533 PSA (G/G Genotype) Mutation Humans Increases risk with G/G Genotype compared with the G/A And A/A genotype Diagnostic Cancer Vs Controls p<0.05 Blood 20632874
534 AR: (Short CAG) Mutation Humans Increased Risk with shorter CAG Repeats Diagnostic Cancer Vs Controls p = 0.007 Blood 20632874
535 PSA and AR (G/G and Short CAG) Mutation Humans Increased Risk of Prostate Cancer Diagnostic Cancer Vs Controls p = 0.0418 Blood 20632874
536 PSA (G/G Genotype) Mutation Humans Increases risk of Gleason Score >=7 with G/G Genotype compared with the G/A & A/A genotype Prognostic Gleason ≤7 Vs Gleason Score >7 p= 0.0122 Blood 20632874
537 AR: (Short CAG) Mutation Humans Increased RIsk of GS (4+3) with Short CAG Repeats Prognostic Gleason Score 7 (4+3) Vs Gleason Score 7 (3+4) p = 0.045 Blood 20632874
585 SLCO2B1 (SNP rs12422149) Mutation Humans Increased risk in GA or AA type allele Prognostic Prostate Cancer Specific Mortality No No mortality p<0.05 Blood 21266523
586 SLCO1B3 (SNP rs4149117) Mutation Humans NA Prognostic Prostate Cancer Specific Mortality No No mortality p<0.05 Blood 21266523
615 Mutation Status of TNFSF10 (SNP: rs3774315 (A/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: 0.0000734; Testing Set: p=0.03 Blood 21467234
616 Mutation Status of FBXO34 (SNP: rs8015211 (T/C)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.0000164 Blood 21467234
617 Mutation Status of FBXO34 (SNP: rs12433615 (A/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.0000406 Blood 21467234
618 Mutation Status of FBXO34 (SNP: rs1188069 (T/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.0000638 Blood 21467234
619 Mutation Status of FBXO34 (SNP: rs2341883 (A/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.0000638 ; Testing Set: 0.01 Blood 21467234
620 Mutation Status of HERC2 (SNP: rs6497287 (T/C)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.000052 ; Test Set: p=0.004 Blood 21467234
621 Mutation Status of WWOX (SNP: rs11150069 (C/A)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.00000943 Blood 21467234
622 Mutation Status of WWOX (SNP: rs4628973 (A/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.000000462 Blood 21467234
623 Mutation Status of IL1RAPL1 (SNP: rs225061 (G/T)) Mutation Humans Associated with Disease Aggressiveness Diagnostic More Aggressive Vs Controls Discovery Set: p= 0.000971 Blood 21467234
624 Mutation Status of TNFSF10 (SNP: rs3774315 (A/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic Less Aggressive Vs Controls Discovery Set: 0.0000734; Testing Set: p=0.002 Blood 21467234
625 Mutation Status of FBXO34 (SNP: rs2341883 (A/G)) Mutation Humans Associated with Disease Aggressiveness Diagnostic Less Aggressive Vs Controls Discovery Set: p= 0.0000638 ; Testing Set: 0.01 Blood 21467234
724 Mutation Status of PER1, SNP: rs885747 Mutation Humans NA Diagnostic Controls Vs More Agressive Disease p<0.05 Blood 19934327
725 Mutation Status of PER1, SNP rs2289591 - T/T Phenotype Mutation Humans NA Diagnostic Controls Vs More Agressive Disease p<0.05 Blood 19934327
726 Mutation Status of PER1, SNP: rs885747 - G/T + T/T Phenotype Mutation Humans NA Diagnostic Controls Vs More Agressive Disease p<0.05 Blood 19934327
727 Mutation Status of PER2, SNP: rs7602358: T/G phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
728 Mutation Status of PER2, SNP: rs7602358: T/G+G/G phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
729 Mutation Status of PER3,SNP: rs1012477: C/G phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
730 Mutation Status of PER3,SNP: rs1012477: C/G + C/C phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
731 Mutation Status of CSNK1E SNP: rs1534891: T/T phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
732 Mutation Status of CSNK1E SNP: rs1534891: T/T phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
733 Mutation Status of CRY1 SNP: rs12315175 ; C/C Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
734 Mutation Status of ARNTL, SNP: rs795022; G/A Phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
735 Mutation Status of ARNTL, SNP: rs795022; G/A+A/A Phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
736 Mutation Status of ARNTL, SNP: rs795022; G/A Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
737 Mutation Status of ARNTL, SNP: rs795022; G/A+A/A Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
738 Mutation Status of CLOCK, SNP: rs11133373, G/G Phenotype Mutation Humans NA Diagnostic Controls Vs More Agressive Disease p<0.05 Blood 19934327
739 Mutation Status of CLOCK, SNP: rs11133373, G/G + C/G Phenotype Mutation Humans NA Diagnostic Controls Vs More Agressive Disease p<0.05 Blood 19934327
740 Mutation Status of NPAS2, SNP: rs1369481, G/A Phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
741 Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
742 Mutation Status of NPAS2, SNP: rs1369481, G/A Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
743 Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
744 Mutation Status of NPAS2, SNP: rs895521 G/A Phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
745 Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
746 Mutation Status of NPAS2, SNP: rs1369481, G/A+A/APhenotype Mutation Humans NA Diagnostic Controls Vs More Agressive Disease p<0.05 Blood 19934327
747 Mutation Status of NPAS2, SNP: rs1369481, T/C Phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
748 Mutation Status of NPAS2, SNP: rs1369481, T/C + CC Phenotype Mutation Humans NA Diagnostic Controls Vs Cancer p<0.05 Blood 19934327
749 Mutation Status of NPAS2, SNP: rs1369481, T/C Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
750 Mutation Status of NPAS2, SNP: rs1369481, C/C Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
751 Mutation Status of NPAS2, SNP: rs1369481, T/C+C/C Phenotype Mutation Humans NA Diagnostic Controls Vs Less Agressive Disease p<0.05 Blood 19934327
834 Mutation Status of StAR Mutation Humans Allelic Loss in StAR in Recurrence Prognostic Biochemical Recurrenece (5 years) p=0.00269 Tissue 22213075
835 Mutation Status of HSD17B2 Mutation Humans Allelic Loss in HSD17B2 in Recurrence Prognostic Biochemical Recurrenece (5 years) p=0.031 Tissue 22213075
836 Mutation Status of StAR or HSD17B2 Mutation Humans Allelic Loss in atleast one (HSD17B2 or StaR) in Recurrence Prognostic Biochemical Recurrenece (5 years) p=0.0028 Tissue 22213075
932 Modification Status of RNF219 cirDNA Humans Highly modified in PCa Patients (Control: 55% Diagnostic PCA VS no history of prostate disease p=3 *10^-41 Plasma 22619380
933 Modification Status of RNF220 cirDNA Humans Highly modified in PCa Patients (Control: 55% Diagnostic PCA Vs BPH p = 1 *10^-4 Plasma 22619380
937 TMPRSS2:ERG Fusion mRNA Humans Upregulated (RQ = NP: 0.6 Vs LG = 11) Diagnostic Normal adjacent to Prostate (NP) Vs Low Grade PCa <0.005 Tissue 22674214
941 Mutation Status of KLK3 (-5429 T/G (rs2569733)) Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) Univariate Analysis: <0.01 ; Multivariate Analysis : p=0.013 Blood 22759231
942 Mutation Status of KLK2 (Arg250Trp (rs198977)) Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) Univariate Analysis: p=0.025 ; Multivariate Analysis : p=0.044 Blood 22759231
943 Mutation Status of SULT1A1, Arg213His (rs9282861) Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) Univariate Analysis: 0.014 Blood 22759231
944 Mutation Status of BGLAP, -198 T/C (rs1800247) Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) Univariate Analysis: <0.01 ; Multivariate Analysis : p=0.020 Blood 22759231
945 Mutation Status of KLK3 + KLK2 + SULT1A1 + BGLAP + Nonogram Mutation Humans NA Prognostic Biochemical Recurrence Vs no Biochemical Recurrence (5 years) p<0.001 Blood 22759231
946 Mutation Status of LEPR (LEPR Gln223Arg) Mutation Humans Increased Risk of PCa Diagnostic LEPR Gln223Arg ( A Vs G mutation) in All patients with Prostate Cancer NA NA 22792137
947 Mutation Status of SPP1 (SPP1-66 T>G) Mutation Humans Increased Risk of PCa Diagnostic SPP1 mutaion (SPP1- 66 T>G) in All patients with Prostate Cancer NA NA 22792137
948 Mutation Status of IGF1R (IGF1R+3174 G>A) Mutation Humans Increased Risk of PCa Diagnostic IGF1R mutation (IGF1R+3174 G>A) in All patients with Prostate Cancer NA NA 22792137
949 Mutation Status of IGFBP3 (IGFBP3-202 A>C) Mutation Humans Increased Risk of PCa Diagnostic IGFBP3 mutation (IGFBP3-202 A>C) in All patients with Prostate Cancer NA NA 22792137
950 Mutation Status of FGF2 (FGF2+223 C>T) Mutation Humans Increased Risk of PCa Diagnostic FGF2 mutation (FGF2+223 C>T) in All patients with Prostate Cancer NA NA 22792137
951 Mutation Status of IL6 (IL6-597 G>A) Mutation Humans Increased Risk of PCa Diagnostic IL6 mutation (IL6-597 G>A) in All patients with Prostate Cancer NA NA 22792137
952 Mutation Status of LEPR (LEPR Gln223Arg) Mutation Humans Increased Risk of High Grade PCa Prognostic LEPR Gln223Arg ( A Vs G mutation) in Patients with High Grade PCa NA NA 22792137
953 Mutation Status of SPP1 (SPP1-66 T>G) Mutation Humans Increased Risk of High Grade PCa Prognostic SPP1 mutaion (SPP1- 66 T>G) in Patients with High Grade PCa NA NA 22792137
954 Mutation Status of IGF1R (IGF1R+3174 G>A) Mutation Humans Increased Risk of High Grade PCa Prognostic IGF1R mutation (IGF1R+3174 G>A) in Patients with High Grade PCa NA NA 22792137
955 Mutation Status of IGFBP3 (IGFBP3-202 A>C) Mutation Humans Increased Risk of High Grade PCa Prognostic IGFBP3 mutation (IGFBP3-202 A>C) in Patients with High Grade PCa NA NA 22792137
956 Mutation Status of FGF2 (FGF2+223 C>T) Mutation Humans Increased Risk of High Grade PCa Prognostic FGF2 mutation (FGF2+223 C>T) in Patients with High Grade PCa NA NA 22792137
957 Mutation Status of IL6 (IL6-597 G>A) Mutation Humans Increased Risk of High Grade PCa Prognostic IL6 mutation (IL6-597 G>A) in Patients with High Grade PCa NA NA 22792137
958 Mutation Status of LEPR (LEPR Gln223Arg) Mutation Humans Increased Risk of High Grade PCa for Metastasis Prognostic LEPR Gln223Arg ( A Vs G mutation) in Patients with High Grade PCa With Metastasis NA NA 22792137
959 Mutation Status of SPP1 (SPP1-66 T>G) Mutation Humans Increased Risk of High Grade PCa for Metastasis Prognostic SPP1 mutaion (SPP1- 66 T>G) in Patients with High Grade PCa With Metastasis NA NA 22792137
960 Mutation Status of FGF2 (FGF2+223 C>T) Mutation Humans Increased Risk of High Grade PCa for Metastasis Prognostic FGF2 mutation (FGF2+223 C>T) in Patients with High Grade PCa With Metastasis NA NA 22792137
1089 Ribonuclease -L (RNASEL) [Arg462Gln Mutation] Mutation Humans Increased Risk of PCA in African Population Diagnostic Cases Vs Controls p<0.05 NA 23554651
1090 Ribonuclease -L (RNASEL) [Arg462Gln Mutation] Mutation Humans Increased Risk of PCA Diagnostic Cases Vs Controls p<0.05 NA 23554651
1143 RFX6 (rs339331) Mutation Humans Reduced Risk of Prostate cancer Diagnostic Cancer Vs Normal p= 0.013 Blood 23803082
1146 Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;] mRNA Humans Upregulated in PCa Diagnostic Prostate Cancer Vs Benign Prostatic Hyperplasia NA Tissue 23813660
1147 Copy Number Alterations: [PTP4A3; LOC440335; SERPINE1; PKN1; JUNB; GDF15; CLDN4; CLDN3; LOC644844; ZNF511;FOSB; FMOD; ZFP36; RASD1;ODC1; HSD17B6; GADD45G; APOF; TUBB2A; PGC; NR4A1; LOC145837; FOS; FBP1;] mRNA Humans Upregulated in PCa Diagnostic Agressive Vs Non Agressive Prostate Cancer NA Tissue 23813660
1177 Genetic Risk score based on 41 SNPs (rs10187424, rs721048, rs1465618, rs13385191, rs12621278, rs2292884, rs4857841, rs6763931, rs10936632, rs17021918, rs12500426, rs7679673, rs2121875, rs12653946, rs130067, rs1983891, rs339331, rs9364554, rs10486567, rs6465657, rs1512268, rs1447295, rs6983561, rs16901979, rs10086908, rs12543663, rs620861, rs6983267, rs16902094, rs1016343, rs13252298, rs445114, rs10993994, rs4962416, rs10896449, rs11228565, rs12418451, rs10875943, rs9600079, rs4430796, rs11649743, rs1859962, rs8102476, rs17632542, rs2735839, rs9623117, rs5759167, rs5945619, rs5919432) Mutation Humans Increased Score with Increased risk of Prostate Cancer Diagnostic Prostate Cancer Vs no Prostate Cancer Univariate: p=0.014; Multivariate: 0.029 Blood 23891454
1178 SLCO2B1 rs12422149 (GG allele) Mutation Humans NA Prognostic Time to Progression p =0.028 Blood 23896625
1208 RNASEL [D541E variant: GG] Mutation Humans Expressed in patients with High Risk of PCa Prognostic High Risk with GG phenotype Vs High Risk with (TG and TT phenotype) p≤ 0.001 Blood 24046815
1209 RNASEL [R462Q variant: AA] Mutation Humans Expressed in patients with High Risk of PCa Prognostic High Risk with AA phenotype Vs High Risk with (AA and GA phenotype) p≤ 0.001 Blood 24046815
1210 Copy Number Variation: Deletion of 2p24.3 Mutation Humans Deletion found in Hispanic patients with High Risk PCa Prognostic High Risk Vs Low Risk p = 0.007 Blood 24054869
1308 C2orf43 [SNP: rs13385191] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.05 Blood 24411283
1309 PDLIM5 [SNP: rs17021918] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.01 Blood 24411283
1310 JAZF1 [SNP: rs10486567] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.001 Blood 24411283
1311 LMTK2 [SNP: rs6465657] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.02 Blood 24411283
1312 MSMB [SNP: rs10993994] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.02 Blood 24411283
1313 SNP: rs7127900 Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.01 Blood 24411283
1314 SNP: rs11672691 Mutation Humans Increased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.007 Blood 24411283
1315 KLK3 [SNP: rs2735839] Mutation Humans Decreased risk of PCa Specific Mortality Prognostic PCa Specific Mortality Vs No Mortality p=0.002 Blood 24411283
1316 FRK [SNP: rs171866: AA versus gg/gA] Mutation Humans Increased risk of Progression Prognostic Progression Vs No Progression During ADT p=0.015 Blood 24448834
1317 DAB2 [SNP: rs268091: GC/CC versus GG] Mutation Humans Increased risk of Progression Prognostic PCa Specific Mortality Vs No Mortality During ADT p=0.012 Blood 24448834
1318 DAB2 [SNP: rs268091: CC versus GG/GC] Mutation Humans Increased risk of Progression Prognostic PCa Specific Mortality Vs No Mortality During ADT p=0.031 Blood 24448834
1319 EXOC4: [SNP: rs1149558: TT versus CC/CT] Mutation Humans Increased risk of Progression Prognostic PCa Specific Mortality Vs No Mortality During ADT p=0.014 Blood 24448834
1320 EXOC4: [SNP: rs1149558: TT versus CC/CT] Mutation Humans Increased risk of Progression Prognostic All Cause Mortality Vs No Mortality during ADT p=0.005 Blood 24448834
1354 COMT [SNP: rs11705619: T>C] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.041 Blood 24682418
1355 COMT [SNP: rs165849: A>G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.047 Blood 24682418
1356 COMT [SNP: rs9332377: C>T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.017 Blood 24682418
1357 CYP1B1 [SNP: rs1800440: A>G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.016 Blood 24682418
1358 NQO1 [SNP: rs2917670: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.039 Blood 24682418
1359 NQO2 [SNP: rs10223369: C>T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.002 Blood 24682418
1360 NQO2 [SNP: rs1143684: T>C] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.030 Blood 24682418
1361 NQO2 [SNP: rs6920900 G>C] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.007 Blood 24682418
1362 SULT2B1 [SNP: rs12460535: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.017 Blood 24682418
1363 SULT2B1 [SNP: rs2665582: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.037 Blood 24682418
1364 COMT [ SNP: rs16982844: C>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Blood 24682418
1365 CYP1B1: [SNP: rs1800440: A>G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.0009 Blood 24682418
1366 SULT2B1: [SNP: rs10426628: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.025 Blood 24682418
1367 SULT2B1: [SNP: rs12460535: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.028 Blood 24682418
1368 SULT2B1: [SNP: rs2665582: G>A] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.07 Blood 24682418
1407 MIR605 [SNP: rs2043556: GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.006 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.005 Cohort 1+2: p=0.01 Blood 24740842
1408 MIR605 [SNP: rs2043556: AG/GG vs. AA] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.04 Cohort 1+2: p=0.02 Blood 24740842
1409 MIR605 [SNP: rs2043556: GG vs. AA/AG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.02 Cohort 1+2: p=0.03;Multivariate: Cohort 1:p = 0.004 Cohort 1+2: p=0.01 Blood 24740842
1410 MTRR [SNP: rs9332: CT] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.008 Cohort 1+2: p=0.01 Blood 24740842
1411 MTRR [SNP: rs9332: CT/TT vs. CC] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.04 Cohort 1+2: p=0.05 Blood 24740842
1412 CDON [SNP: rs3737336: CC] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1: p= 0.05 Cohort 1+2: p=0.01;Multivariate: Cohort 1:p = 0.03 Cohort 2: p = 0.04 Cohort 1+2: p=0.003 Blood 24740842
1413 CDON [SNP: rs3737336: CC vs. TT/TC] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence Univariate: Cohort 1+2: p=0.02;Multivariate: Cohort 1: p = 0.03; Cohort 1+2: p=0.007 Blood 24740842
1574 RNASEL (SNP: rs635261) Mutation Humans NA Prognostic PCa-specific mortality Vs No PCa-specific mortality p= 0.002 Blood 25273821
1575 XRCC1 (SNP: rs915927) Mutation Humans NA Prognostic PCa-specific mortality Vs No PCa-specific mortality p=0.009 Blood 25273821
1576 AKT1 (SNP: rs2494750) Mutation Humans NA Prognostic PCa-specific mortality Vs No PCa-specific mortality p=0.016 Blood 25273821
1577 (Intergenic) KLK3–KLK2: [SNP: rs2735839] Mutation Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score ≥ 8 p=0.002 Blood 25274378
1578 JAZF1 [SNP: rs10486567] Mutation Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score ≥ 8 p=0.012 Blood 25274378
1579 (Intergenic) LILRB2–LILRA3 [SNP: rs103294] Mutation Humans NA Prognostic Gleason Score ≤ 6 Vs Gleason Score ≥ 8 p=0.024 Blood 25274378
1580 (Intergenic) KLK3–KLK2: [SNP: rs2735839] (AG/GG) Mutation Humans NA Prognostic Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3) p=0.0002 Blood 25274378
1581 (Intergenic) KLK3–KLK2: [SNP: rs2735839] (AG+AA/GG) Mutation Humans NA Prognostic Gleason Score 7 (3+4) Vs Gleason Score 7 (4+3) p=0.0005 Blood 25274378
1612 IL2RB [SNP: rs84460; C vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.006 Blood 31035590
1613 SMAD3 [SNP: rs7162912; G vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.0001 Blood 31035590
1614 FOXO3 [SNP: rs7762395 C Vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.002 Blood 31035590
1615 FOXO3 [SNP: rs2153960 C Vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Blood 31035590
1616 SMAD3 [SNP: rs9302242; A vs G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.005 Blood 31035590
1617 IL4R [SNP: rs1805011; A vs C] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.003 Blood 31035590
1618 IL4R [SNP: rs3024586; A vs G] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.003 Blood 31035590
1619 CCL5 [SNP: rs2280789 C Vs T] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.001 Blood 31035590
1620 MMP9 [SNP: rs3918262; A Vs G] Mutation Humans NA Prognostic Overall Survival Vs No Overall Survival p=0.001 Blood 31035590
1621 VEGFR2 [SNP: rs7692791; C Vs T] Mutation Humans NA Prognostic Overall Survival Vs No Overall Survival p=0.001 Blood 31035590
1622 VEGFR2 [SNP: rs2034967; C Vs T] Mutation Humans NA Prognostic Overall Survival Vs No Overall Survival p=0.00000008 Blood 31035590
1714 TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 GG/AA] Mutation Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.003 Blood 26238235
1715 TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AG/AA] Mutation Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer p=0.005 Blood 26238235
1716 TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AA vs GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.032 Blood 26238235
1717 TEP1 (Telomerase Associated Protein 1) [SNP: rs1760904 AG/AA Vs GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.002 Blood 26238235
1718 TNKS2 (Tankyrase 2) [SNP: rs1539042 CG Vs GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.032 Blood 26238235
1719 TNKS2 (Tankyrase 2) [SNP: rs1539042 CG/CC Vs GG] Mutation Humans NA Prognostic Biochemical recurrence Vs No Biochemical Recurrence p=0.02 Blood 26238235
1759 AHNAK2; ANKRD30A; ANKRD36C; APOB; ATP13A5; BAI3; CACNA1A; CACNA1E; CDH23; CNTNAP5; EPB41L3; FAM47C; FAT2; FAT4 ;FBN3; FLG2; FRG1B; HSPG2; KMT2D; KRTAP4-9; LPHN3; MUC16; SACS; MUC4; SALL1; MYH11; SCN5A; MYT1L; SPOP; NOD1; SRCAP; PCDHA12; TP53; PIK3CA; TRPM6; PTEN; USH2A; PTH2; ZNF208; PTPRC; ZNF91;RYR1; MUC2; Mutation Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA NA 29158798
1760 PSA concentration+Gleason grade+clinical T stage+ AHNAK2; ANKRD30A; ANKRD36C; APOB; ATP13A5; BAI3; CACNA1A; CACNA1E; CDH23; CNTNAP5; EPB41L3; FAM47C; FAT2; FAT4 ;FBN3; FLG2; FRG1B; HSPG2; KMT2D; KRTAP4-9; LPHN3; MUC16; SACS; MUC4; SALL1; MYH11; SCN5A; MYT1L; SPOP; NOD1; SRCAP; PCDHA12; TP53; PIK3CA; TRPM6; PTEN; USH2A; PTH2; ZNF208; PTPRC; ZNF91;RYR1; MUC2; Mutation Humans NA Diagnostic Prostate Cancer Vs No Prostate Cancer NA NA 29158798
1889 Interleukin 8 [SNP: rs4073 A vs T] Mutation Humans Isoform 2 of Eukaryotic translation initiation factor 2‐alpha kinase 4 (4 fold); Keratin type I cytoskeletal 10; SCO‐spondin (10 fold); Serum amyloid P‐component (4 fold); Apolipoprotein(a) (4 fold); Keratin, type I cytoskeletal 9 (3 fold); Ig kappa chain V‐IV region (2.4 fold); Isoform 2 of Filamin A (2.4 fold); Keratin, type II cytoskeletal 1(2.6 fold); Keratin, type II cytoskeletal 2 epidermal (2.3 fold); Diagnostic/Prognostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.002 Blood 30641210
1890 Interleukin 8 [SNP: rs4073 AA vs TT] Mutation Humans Ig heavy chain V‐III region BRO (0.1‐fold); Alpha‐1‐antitrypsin (0.1‐fold); Plasminogen (0.1‐ fold); Ig heavy chain V‐III region TIL (0.1‐fold); Hemopexin (0.1‐fold); Afamin (0.1‐fold); Inter‐alpha‐trypsin inhibitor heavy chain H1 (0.1‐fold); Protein AMBP (0.1‐fold); Alpha‐1B‐glycoprotein (0.03‐fold); Complement component C8 alpha chain (0.06‐fold); Diagnostic/Prognostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.002 Blood 30641210
1891 Interleukin 8 [SNP: rs4073 AA vs. TA+TT] Mutation Humans Downregulated in PCa: [4-(3,4-dihydro-2,2,4-trimethyl-2H-1-benzopyran-4-yl)-phenol; Estradiol; Ethyl à-hydroxymyristate trisiloxane; 1-(2,4-Dimethylphenyl)-3-(tetrahydrofuryl-2)propane; 2-amino-Imidazole-5-carboxylic acid; ] Upregulated in PCa: [1,1,3,3,5,5,7,7,9,9-decamethyl-pentasiloxane; 1,1,1,5,5,5-hexamethyl-3,3-bis[(trimethylsilyl)oxy]-Trisiloxane; Phthalic acid, bis(7-methyloctyl) ester; 4-Nitro-4’-chlorodiphenylsulfoxide; 1-Propylpentachlorotriphosphazene; 2,6-di-t-butyl-4-hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone] Diagnostic/Prognostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.03 Blood 30641210
1892 Interleukin 8 [SNP: rs1126647 TT vs AA] Mutation Humans NA Diagnostic/Prognostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.02 Blood 30641210
1893 Interleukin 8 [SNP: rs1126647 TT vs AA + AT] Mutation Humans NA Diagnostic/Prognostic Prostate Cancer Vs Benign Prostatic hyperplasia p=0.02 Blood 30641210